TRI-LO-LINYAH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-LO-LINYAH (TRI-LO-LINYAH).
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
| Metabolism | Hepatic metabolism via CYP3A4 isoenzymes; ethinyl estradiol undergoes conjugation (sulfation and glucuronidation), while norgestimate is rapidly deacetylated to norelgestromin (active metabolite) and further hydroxylated and conjugated. |
| Excretion | Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites. |
| Half-life | Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment. |
| Protein binding | Approximately 99% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 80-90% (high bioavailability). |
| Onset of Action | Oral: peak plasma concentration at 2-4 hours, clinical effect within 24 hours. |
| Duration of Action | 24 hours (once-daily dosing); steady state achieved after 5-7 days. |
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment or end-stage renal disease; use with caution due to potential fluid and electrolyte changes. |
| Liver impairment | Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Use caution in Child-Pugh class A or B; start with lowest effective dose if benefits outweigh risks, as steroids may be less well metabolized. |
| Pediatric use | Approved for postmenarchal adolescents; dosing same as adults. Safety and efficacy in premenarchal patients not established. |
| Geriatric use | Not indicated for use in postmenopausal women. No specific dose adjustment studies; use generally avoided due to increased risk of thromboembolism and cardiovascular events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRI-LO-LINYAH (TRI-LO-LINYAH).
| Breastfeeding | Contraindicated in breastfeeding. Small amounts of hormonal contraceptives are excreted in breast milk; however, due to potential adverse effects on the nursing infant, use is not recommended. M/P ratio not established. |
| Teratogenic Risk | Pregnancy Category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and limb defects, and increased risk of miscarriage. Use should be discontinued if pregnancy occurs. |
| Fetal Monitoring |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from combined oral contraceptive use. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use combined oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
["History of or current venous/arterial thromboembolic events (e.g., DVT, PE, stroke, MI).","Known thrombophilic disorders (e.g., factor V Leiden, prothrombin mutation).","Cerebrovascular or coronary artery disease.","Uncontrolled hypertension (BP >160/100 mmHg).","Diabetes with vascular involvement.","Migraine with focal aura (especially if age >35).","Active liver disease (e.g., hepatitis, cirrhosis) or hepatic tumors.","Known or suspected breast carcinoma or estrogen-dependent neoplasia.","Undiagnosed abnormal uterine bleeding.","Pregnancy or suspected pregnancy.","Hypersensitivity to any component.","Smoking in women >35 years (relative contraindication; absolute if heavy smoker).","Major surgery with prolonged immobilization (relative contraindication)."]
| Precautions | ["Increased risk of thromboembolic disorders (venous and arterial), especially in smokers, obesity, hypertension, or hyperlipidemia.","Elevated risk of hepatic neoplasia (benign and malignant).","Worsening of depression, migraine, or glucose tolerance.","May cause fluid retention, hypertension, irregular bleeding, or amenorrhea.","Cessation if jaundice, visual disturbances, or thrombotic events occur."] |
Loading safety data…
| Not applicable for ongoing use as drug is contraindicated in pregnancy. If inadvertent exposure occurs, monitor for fetal anomalies via ultrasound and consider fetal echocardiography. |
| Fertility Effects | Suppresses ovulation and may delay return to fertility after discontinuation. No permanent effects on fertility expected. |